This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

DaVita Closes Deal To Provide Dialysis Services In Taiwan

DaVita®, the kidney care division of DaVita HealthCare Partners Inc. (NYSE: DVA) and a leading provider of kidney care services, today announced the formation of a joint venture with Riches Healthcare (RHC), through which a new entity – DaVita Taiwan – will provide services to four dialysis clinics. DaVita will own a majority share of the joint venture entity.

"Expanding our presence into Taiwan is a key step in our long-term growth strategy in Asia," said Dennis Kogod, chief operating officer at DaVita.

The four clinics currently serviced by RHC are located in and around Taipei, have a combined number of 88 stations and are providing hemodialysis treatments to more than 250 patients.

“This acquisition is an exciting opportunity not only to expand into Taiwan, but also to do so with a well-respected and highly experienced team,” said Atul Mathur, president of Asia Pacific at DaVita. “With the addition of this JV, DaVita is now serving patients in five countries across the Asia Pacific region.”

As a leading provider of kidney care services in the United States, DaVita has achieved clinical outcomes that have improved year-over-year for more than a decade and plans to bring that track record of sustained clinical excellence to Taiwan.

For more information on DaVita please visit www.DaVita.com.

DaVita® is a registered trademark, and DaVita HealthCare Partners is a service mark, of DaVita HealthCare Partners Inc. All other marks are the property of their respective owners.

About DaVita

DaVita is the dialysis division of DaVita HealthCare Partners Inc., a Fortune 500® company. A leading provider of kidney care in the United States, DaVita delivers dialysis services to patients with chronic kidney failure and end stage renal disease. DaVita strives to improve patients’ quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health-management services. As of Sept. 30, 2012, DaVita operated or provided administrative services at 1,912 outpatient dialysis centers located in the United States serving approximately 150,000 patients. The company also operated 24 outpatient dialysis centers located in five countries outside the United States. DaVita supports numerous programs dedicated to creating positive, sustainable change in communities around the world. The company’s leadership development initiatives and social responsibility efforts have been recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the federal securities laws, including statements related to prospective near-term and long-term growth, development, strategy and expectations for certain of our international operations, anticipated patient benefits and projected clinical outcomes. Factors which could impact future results include the risks and uncertainties associated with expansion of our operations and services to markets outside the United States, local laws and regulations, general economic and other market conditions, competition, and the risk factors set forth in our SEC filings, including our Annual Report on Form 10-K for the year ended December 31, 2011, and our subsequently filed Quarterly Reports on Form 10-Q. The forward-looking statements should be considered in light of these risks and uncertainties. We base our forward-looking statements on information currently available to us at the time of this release, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of changes in underlying factors, new information, future events or otherwise.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,698.21 -47.77 -0.27%
S&P 500 2,108.06 -0.57 -0.03%
NASDAQ 5,130.9280 +2.1430 0.04%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs